Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoPeCa: MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis
NCT02219893Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Aug 2014
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MOC31-PE in colorectal cancer (CRC), sponsored by Oslo University Hospital. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 5 years. Started Aug 2014; status: completed.
02
Drugs
MOC31-PE
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02219893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219893.